Baili Tianheng made a profit of 3.7 billion yuan, and R&D expenses increased by 93%, and it is planned to increase the number of innovative drugs by 3.9 billion
DATE:  Apr 02 2025

Yangtze River Business Daily News ● Yangtze River Business Daily reporter Wang Jing

Innovative drugs have successfully gone overseas, and Baili Tianheng (688506. SH) has finally achieved a turnaround.

The annual report shows that in 2024, Baili Tianheng will achieve operating income of 5.823 billion yuan, a year-on-year increase of 936.31%; The net profit was 3.708 billion yuan, a year-on-year turnaround.

The

strategic cooperation transaction with Bristol-Myers Squibb (BMS) for BL-B01D1 with a down payment of US$800 million and a total of US$8.4 billion was the reason for Baili Tianheng's turnaround.

While achieving breakthroughs in business performance, Baili Tianheng has steadily promoted the research and development of innovative biological drugs, has 14 drug candidates in the clinical stage, and has conducted more than 70 clinical trials around the world. Baili Tianheng is promoting the private placement and plans to raise no more than 3.9 billion yuan for innovative drug research and development projects. At the same time, the company is also promoting its listing in Hong Kong.

In the secondary market, on April 1, Baili Tianheng's share price hit a new high intraday, closing at 248.5 yuan / share, up 9 times from the IPO issue price of 24.7 yuan / share, and the current total market value reached 99.6 billion yuan.

Ushered in a profit inflection point

Recently, Baili Tianheng's 2024 annual report was released, and the company's annual operating income was 5.823 billion yuan, a year-on-year increase of 936.31%; The net profit was 3.708 billion yuan, an increase of 4.488 billion yuan over the same period of last year, turning losses into profits year-on-year.

In the

past 2021-2023, Baili Tianheng continued to lose money, and for 2024 to usher in a profit inflection point, Baili Tianheng said that it was mainly due to the company's receipt of an irrevocable and non-deductible down payment of 800 million US dollars from BMS, an overseas partner of the core product BL-B01D1 (EGFR×HER3 bispecific antibody ADC), based on the cooperation agreement.

It is reported that BL-B01D1 is the world's first-in-class, newconcept, and the only EGFR×HER3 bispecific antibody antibody conjugate (ADC) that has entered the phase III clinical stage. In December 2023, Baili Tianheng entered into a strategic cooperation with BMS, a global multinational pharmaceutical company, with a potential total transaction value of up to US$8.4 billion (US$800 million down payment, US$500 million in recent contingent payments, and US$7.1 billion in milestone payments) to obtain the right to co-develop and co-commercialize with the company, which is responsible for the development, commercialization and production of BL-B01D1 in Chinese mainland, and is responsible for the production of some drugs for use outside Chinese mainland.

It is reported that this transaction has set a new record for the total transaction price of a single product of global ADC drugs, and also set a record for the down payment and total transaction value of domestic innovative drug strategic cooperation transactions.

With the successful launch of innovative drugs, Baili Tianheng's overseas revenue will reach 5.331 billion yuan in 2024, accounting for 91.55% of the revenue.

In addition, in 2024, Baili Tianheng will also accelerate the global clinical research process of BL-B01D1 for multiple cancer types. According to the annual report, BL-B01D1 obtained nearly 10 clinical trial approvals last year, and more than 30 clinical trials for more than 10 tumor types have been carried out in China and the United States, basically covering different tumor indications such as lung cancer, breast cancer, digestive tract tumors, urological tumors, gynecological tumors and head and neck tumors.

R&D expenses amounted to 1.443 billion

In 2014, Baili Tianheng started the road of transformation and innovative drugs and established a biotech company SystImmune in Seattle. In the following five years, Baili Tianheng built a technology platform including monoclonal antibodies, bispecific antibodies, multi-specific antibodies, ADCs and fusion proteins.

From 2020 to 2023, its R&D expenses will be 196 million yuan, 279 million yuan, 375 million yuan, and 746 million yuan respectively.

In 2024, Baili Tianheng's R&D expenses will be 1.443 billion yuan, a year-on-year increase of 93.34%. The company's pipeline of innovative drug products has been successfully advanced at home and abroad, with 14 drug candidates in the clinical stage and more than 70 clinical trials conducted worldwide, including more than 10 phase III clinical studies in China and 6 clinical studies in the United States.

At the same time, Baili Tianheng also raised funds from the market and continued to increase the number of innovative drugs.

On the evening of March 9, Baili Tianheng released a fixed increase plan. The company intends to issue no more than 20.05 million shares to no more than 35 specific targets, and the total amount of funds raised will not exceed 3.9 billion yuan, which will be used for innovative drug research and development projects after deducting issuance expenses.

In addition to the plan to increase the number of A-shares, Baili Tianheng is also promoting its listing in Hong Kong. In July 2024, Baili Tianheng submitted its first IPO application on the Hong Kong Stock Exchange. In December of the same year, the company's Hong Kong stock IPO plan was approved by the China Securities Regulatory Commission, and the Listing Committee of the Hong Kong Stock Exchange held a listing hearing to consider the company's application for this issuance and listing.

However, in January this year, due to the expiration of the document, Baili Tianheng submitted the listing documents of the Hong Kong stock market for the second time.

Editor-in-charge: ZB

Follow Yicai Global on

star50stocks

Ticker Name

Percentage Change

Inclusion Date